No More Routine Finger Sticks(1) for Americans with Diabetes

Abbott′s FreeStyle® Libre Approved in the U.S.

- REVOLUTIONARY SYSTEM TO REPLACE BLOOD GLUCOSE MONITORING, ELIMINATING THE NEED FOR ROUTINE FINGER STICKS(1) AND FINGER STICK CALIBRATION

- EASY-TO-USE(2), LONGER LASTING AND LESS BULKY(3) THAN OTHER CONTINUOUS GLUCOSE MONITORS AVAILABLE IN U.S.

- STUDIES SHOW THAT PEOPLE WHO USE THE FREESTYLE LIBRE SYSTEM TEST THEIR GLUCOSE LEVELS MORE FREQUENTLY AND SPEND LESS TIME IN HYPOGLYCEMIA(4,5)

- LOW GLOBAL PRICING STRUCTURE AIMS TO MAKE TECHNOLOGY BROADLY ACCESSIBLE 

ABBOTT PARK, Illinois, Sept. 27, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle^® Libre Flash Glucose Monitoring System as a replacement¹ for blood glucose monitoring (BGM) for adults with diabetes in the U.S. This revolutionary new glucose sensing technology eliminates the need for routine finger sticks¹ and is the only personal continuous glucose monitor (CGM) that does not require finger stick calibration. Designed to be approachable, accessible and affordable for the 30 million people with diabetes in America⁶, the FreeStyle Libre system reads glucose levels through a sensor that is worn on the back of the upper arm for up to 10 days, making it the longest lasting personal glucose sensor available in the U.S. 

Photo - http://mma.prnewswire.com/media/563515/Abbott_FreeStyle_Libre.jpg
Photo - http://mma.prnewswire.com/media/563516/Abbott_FDA_Approval.jpg

The BGM replacement indication means that people with diabetes and their physicians can now make treatment decisions based on information from the FreeStyle Libre system, without the need for painful routine finger sticks¹—and at a fraction of the cost of other CGM systems currently available⁷.

"Today, we are celebrating a breakthrough moment for people with diabetes in the U.S.—an end to the worry and hassles associated with routine finger sticks which have been the standard of glucose testing for more than 40 years," said Jared Watkin, senior vice president, Diabetes Care, Abbott. "At Abbott, we believe that FreeStyle Libre will transform diabetes management and we're proud to be at the forefront of innovation that empowers people to take control of their health to live their best lives."